




























The Faculty of Health Science, UiT The Arctic University of Norway 
Does duration of use of LNG-IUDs vary by contraceptive experience 
of the provider? 
—	
Shaleen Kaur  







Women’s health is an important topic that I have developed a great interest for during my 
years in medical school. It was clear to me that I wanted to write my master thesis related to 
this subject. I was immensely excited when I came in contact with my supervisor, professor 
Finn Egil Skjeldestad, who suggested that I could write about Norwegian women’s use of 
hormonal IUD and contraceptive implants in relation to the contraceptive experience of the 
provider. I found this topic interesting and highly relevant for women today who have several 
choices when it comes to contraceptive methods. Another interesting aspect was that there 
was little to no literature on this topic, thus there was a possibility that the outcome could 
provide some new insight.  
During the early stages of work, we decided to exclude subdermal implants and only focus on 
hormonal IUD in the thesis. This way, the use of hormonal IUD in relation to provider could 
be viewed more thoroughly.  
The journey of writing this thesis has been tough and at times frustrating, but most of all a 
great learning experience. I want to sincerely thank my supervisor, Finn Egil Skjeldestad, 
who has gained access to data, organized the data file and done the more advanced statistical 
methods (survival analysis/Cox regression). This thesis could not have been written without 



































Objective: To evaluate whether duration of LNG-IUD use varies by the contraceptive 
experience of the provider.  
Methods: 49 499 women who had a LNG-IUD prescription during 2010 and 2011 were 
identified from the NorPD database. The contraceptive experience of the providers was 
measured as number of prescriptions for any hormonal contraception, and number of LNG-
IUD prescriptions in 2008/2009. Duration of use was estimated by survival analysis and Cox 
regression models were used to predict determinants of discontinuation.  
Results: General practitioners and gynecologist had the most experience prescribing LNG- 
IUDs. Continuous use of the device increased with age and was highest among older women. 
Providers experience related to number of LNG-IUD prescription before study start did not 
have an effect on duration of use, neither did providers profession. Young women under the 
age of 20 had the highest probability to change to another hormonal contraceptive method 
(Hazard rate 1,97 (95% CI: 1,77 – 2,19)). Women in the age groups 40 – 44 and 45 – 49 were 
more likely to continue their use of LNG-IUD (Hazard rate 0,96 (95% CI: 0,94 – 0,99) and 
Hazard rate 0,96 (95% CI: 0,93 – 0,99), respectively). New user and continuous user of LNG-
IUD were associated with increased probability for changing to another hormonal 
contraceptive method (Hazard rate 1,10 and 1,05, respectively). 
Conclusion: The duration of use of LNG-IUD did not vary by the contraceptive experience 
of the provider. Users age, new use and continuous use of the device was significantly 









LARC  Long Acting Reversible Contraception 
LNG-IUD Levonorgestrel-releasing Intrauterine Device 
COC  Combined Oral Contraceptive  








Levonorgestrel-releasing intrauterine devices (LNG-IUDs) are long acting reversible 
contraceptives (LARCs) and have been available in Norway since 1993. Other types of 
LARCs include copper IUDs and contraceptive implants. The LNG-IUDs are T-shaped and 
contain gestagens in different quantities. They have a lifespan of three to five years depending 
on the gestagen content (amount/dose) (1). 
LNG-IUDs are associated with a high safety profile and are suitable for a broad range of 
women regardless of age and parity(2). They have the advantage of not being user- dependent 
as the contraceptive efficacy is dependent on one single act of insertion. The Norwegian 
Directorate for Health and Social Affairs recommends that more women should be provided 
counselling on the different types of LARCs, including hormonal IUDs, because of the high 
efficacy compared to short acting reversible contraceptive methods (2). LNG-IUDs may 
especially be suitable and cost-effective for certain groups such as young women who are not 
planning to have children in the next few years, women who have recently given birth and 
want space between their pregnancies and parous women who are not planning to become 
pregnant again. 
Studies have shown that LNG-IUDs provide high contraceptive efficacy, with low pregnancy 
rates reported (3-5). LNG-IUDs are also effective in preventing ectopic pregnancies as they 
reduce the overall risk of pregnancy to a minimum(3). However, if a contraceptive failure 
occurs, the possibility of an ectopic pregnancy is somewhat higher, but still low(6) . 
The average use of the LNG-IUD has been reported to be between 69,6% and 80,1% after 1 
year, and between 33,0% and 46,9% after 5 years (3, 4, 7-11). Most terminations occur during 
the first year after insertion, and discontinuation rates are reported to be highest among young 
women, usually under 25 years. After the initial 2 years following insertion, the 
discontinuation rates decrease (3). Duration of LNG-IUD use and premature discontinuation 
can be depended on different factors. Two common reasons for premature discontinuation are 
planning pregnancy and bleeding disturbances.  
Bleeding disturbances and oligo-amenorrhea are well known side effects that often occur 
during the use of LNG-IUDs, and are reasons for early discontinuation among some 





also differ between individuals. Generally, more patients experience spotting and infrequent 
bleedings during the first initial months of use of LNG-IUDs, whereas oligomenorrhea and 
amenorrhea are more commonly experienced after the initial three months (3). Counselling on 
these possible side effects at insertion is important and may reduce premature discontinuation 
rates (3, 4, 8, 11, 12).   
For any contraceptive method, the return of fertility is of importance after termination of any 
method. For women who want to postpone pregnancy by using a contraceptive method, it is 
important that the contraception is effective and that it does not reduce fertility after 
discontinuation. The LNG-IUD has a local and suppressive effect on the endometrium which 
becomes atrophic and inactive during use of the device (13, 14). Studies have shown a normal 
return of endometrial function and fertility after removal of the LNG-IUD, and there seems to 
be no delay in the ability to conceive after removal of the device compared to other 
contraceptive methods (13, 14). 
Difficult and failed insertion of LNG-IUDs have been reported to be low (4, 7, 10, 15). Pain 
at insertion may occur, but sever pain is reported seldom (4, 16, 17). However, there has been 
reported higher rates of difficult insertion and pain at insertion related to the Mirena compared 
to lover dose LNG-IUDs with a narrower insertion tube(16). There has also been described a 
trend toward easier placement of the smaller LNG-IUDs among nulliparous women, which 
might be related to the narrower cervical canal in nulliparous women compared to parous 
women(16).   
Over the years there have been conducted many studies with emphasis on users of LNG-
IUDs. However, the LNG-IUDs has been on the market for many years, thus the interest for 
doing research on these devices is now limited. Another reason for the limited interest in 
research on LNG-IUDs can be the lack of financial support as large clinical trials are costly 
and time consuming.  
There is little, if any, literature at all on contraceptive experience of the providers and if this 
experience is related to duration of use. The main aim of this thesis is to describe the 
providers of hormonal IUD prescription in Norway, and to analyse if their contraceptive 





2 Purpose of the thesis 
To examine whether duration of use of LNG-IUDs varies by contraceptive experience of the 
provider.  
3 Material and methods 
In an historical prospective cohort design, we have analyzed data from the Norwegian 
Prescription Database (NorPD). NorPD was established in 2004, and stores information on 
redeemed prescription in pharmacies. Through a fictitious number created from the personal 
identification number given to all Norwegian citizens at birth or upon immigration, the 
NorPD facilitate data on prescriptions over time denoted users and prescribers. For users, the 
NorPD includes information on month and year of birth, gender and home municipality. 
Detailed information about the drugs is also registered. Prescriber information comprises 
gender, year of birth and graduation, profession, and year and type of medical specialty.  
From January 1st, 2004 through June 30th, 2016, the NorPD database comprised 12 729 909 
prescriptions denoted 939 469 women. From this database we identified 49 783 women who 
had a LNG-IUD prescription during 2010 and 2011. After exclusions of women 50 years or 
older, or age out of range (n=1195), prescriptions to men (n=15), and prescriptions with no 
information on providers’ profession (n=71) nor age (n=3), the study cohort comprised 48 
499 women, all having a Mirena device inserted.  
We estimated duration of use in months from the date of the first collected LNG-IUD 
prescription until the date of expiration of the last continuous LNG-IUD prescription, or date 
of collection of prescription of other hormonal contraceptives. We included women who 
collected other hormonal contraceptives at the same time or within the first 7 days after an 
LNG-IUD prescription, as the user obviously intended to start using a LNG-IUD. Use 
duration for this subset was set to zero months if the user continued to redeem prescription on 
non-LNG-IUD methods. For women not having prescriptions after study start the duration of 
use was set to 60 months, or terminated at study end, June 30th, 2016.  
At study start, we defined switchers as women who took out a LNG-IUD prescription within 
28 days from expiration of the last prescription, if last prescription was combined oral 
contraceptive, a progestogen-only pill, a vaginal ring or a patch.  A time limit was not defined 
where the last hormonal contraceptive was an implant or a LNG-IUD if the duration were 





contraception was restricted to women who submitted a LNG-IUD prescription 29 days or 
later after the most recent collected contraceptive prescription expired. At the study’s end, 
pause denoted women who collected another hormonal contraceptive 180 days or later after 
expiration of the last dispensed LNG-IUD. Continuous LNG-IUD use was denoted women 
who collected another LNG-IUD later than 3 years after study start, or within 180 days after 
the expiration of the device inserted at study start.  
At study start we categorized ever users of a LNG-IUD as users with “new use”, had used a 
LNG-IUD but with another hormonal contraceptive method in between as “past use”, and 
women who had an overlapping duration interval from most recent prescription on a LNG-
IUD to study start as “continuous use”.  
User age was categorized as 15-19, 20-24, 25-29, 30-34, 35-39, 40-44 and 45-49 years, 
whereas prescriber age was categorized as 24-34, 35-44, 45-54, 55-64 and 65-88 years.  
Prescribers’ profession included general practitioner, gynaecologist, and medical doctors with 
another speciality. We denoted physicians without specialist status as doctors with “no 
speciality”. This category includes postgraduate students from medical school during their 
internships, physicians in a residency-training program, and medical students who have valid 
license issued in the fifth year of medical school. Physicians with more than one speciality 
were denoted the most recent speciality.  
The contraceptive experience of the providers was measured as number of prescription for 
any hormonal contraception, and number of LNG-IUDs prescriptions over the last two years 
prior study start (2008/2009) using 40 yearly working weeks as denominator. We categorized 
experience on prescriptions on hormonal contraception as < 1 a month, ≥ 1 a month, 1-9 a 
week, and ≥ 10 a week.  Accordingly, we categorized prescriptions on LNG-IUD as < 1 per 6 
months, < 1 per month and ≥ 1 per month.  
All analysis were done in SPSS version 25.0 (IBM Corp., Armonk, NY, USA) with chi- 
square tests for categorical variables, and t-test for continuation variables. Duration of use 
estimated by survival analysis and Cox regression models were used to predict determinants 
of discontinuation. All analysis applied a significant level p< 0.05. The main exposure was 





The board of the NorPD reviewed the protocol and gave permission for use of data. Studies 
using anonymously data from nationwide registers are by Norwegian legislation exempted 
from institutional regulatory board approvals and written informed consent from patients.  
	
4 Results: 
4.1 Characteristics of providers 
In total 6257 medical doctors provided 48 499 LNG-IUD prescriptions in 2010 and 2011. 
Doctors without speciality (50,5%) and general practitioners (39,4%) were the main 
providers. We anticipate that the doctors prescribing LNG-IUDs also inserted the device.  
Doctors with no speciality were in general younger compared to other providers, with 57% of 
them in the age group 24 – 34 years (Table 1). General practitioners, doctors with another 
medical speciality and gynaecologists were older, with a relative even age distribution.  
Among medical doctors without speciality, women were in majority and represented 59,4% 
of them (Table 1). There was a predominance of men among general practitioners and doctors 
with another speciality. The gender distribution among gynaecologists was somewhat equal, 
with a slightly higher percentage of men.  
As professions, general practitioners and gynaecologists had more experience prescribing 
hormonal IUDs than doctors without and doctors with other specialities. Whereas nearly 23% 
of gynaecologists and 17% of general practitioners prescribed monthly LNG-IUDS, only 4% 
of doctors without speciality and 1% of doctors in other specialities reached this prescription 
volume.  
There was a similar distribution of experience by provider two years before study and in the 
study. General practitioners and gynaecologist prescribed the most hormonal IUD’s during 
both periods.  
General practitioners prescribed a high rate of prescriptions for other hormonal contraception. 
Around 94% of these doctors prescribed more than one prescription of hormonal 
contraception a week. In comparison, 52% of gynaecologists prescribed more than 1 





4.2 Characteristics of users by age 
Analysing users by health region, there was a larger distribution of LNG-IUD in East Norway 
for all age groups (Table 2). The distribution rates were lowest in North Norway. This most 
likely reflects the number of women in the denominator. Each health region had a more or 
less steady percentage of prescriptions prescribed to the different age groups. 
New use of hormonal IUD was highest among women in the age group 15 – 19 years, and 
near 99% of young women in this group had never used a LNG-IUD before. New use of 
hormonal IUD decreased with age. Continuous use of hormonal IUD increased with age and 
was noticeable higher among older women compared to young women.  
The number of women who had not used any contraception prior to the hormonal IUD 
prescribed during the study, increased with age. The most common previous method of 
contraception was combined oral contraceptives (COCs) and progestogen-only-pills (POPs), 
and the use of these contraceptive methods was highest in the youngest age group and 
decreased with age. Having a pause in the use of contraception was more widespread among 
young women compared to women in the older age groups. Around 69% of women with age 
20 – 24 years compared to around 29% of women with age 45 – 59 years had a pause in their 
contraceptive use before starting with a LNG-IUD.  
As providers, doctors with no speciality were the main providers for LNG-IUD prescriptions 
for women in the two youngest age groups. Young women also had more frequently young 
doctors with age between 24 – 34 years as prescribers. In comparison, general practitioners 
were the main providers for women older than 24 years, and doctors who were 45 years or 
older prescribed more often to “older” women.  
A majority of women between age 15 – 39 years did not have the same medical doctor as 
provider for most recent contraceptive prescription before study start. The youngest age group 
(15 – 19 years) had the highest percentage (68%) of women with a different provider. In the 
two oldest age groups, there was nearly an even distribution of women who had the same 
doctor and did not have the same doctor for most recent contraceptive prescription prior to 
study start.  
4.3 Duration of LNG-IUD use 
Providers experience related to number of LNG-IUD prescription before study start did not 





(Table 3). Users age and previous use of hormonal IUD had a significant effect on the 
duration of use of LNG-IUD. Young women under 20 years had the highest risk for switching 
to another hormonal contraceptive method (Hazard rate 1,97 (95% CI: 1,77 – 2,19)). Women 
between 20 – 34 years in the following three age groups also had a higher probability of 
changing to another hormonal contraceptive method. Women between 40 – 49 years were 
more likely to continue the use of hormonal IUD (Hazard rate 0,96). New use and continuous 
use of LNG-IUD were associated with increased probability to change to another hormonal 
contraceptive method (Hazard rate 1,10 and 1,05 respectively). Past use of LNG-IUD did not 
have a significant effect on duration of use of the device.  
Figure 1 shows that the cumulative probability of change to another hormonal method 
(discontinuation rate) by age was highest among young women between 15 – 19 years and 
decreased with age. For all age groups the probability to change to another hormonal 
contraception increased with duration of use.  
5 Discussion:  
As professions, general practitioners and gynecologist had the most experience prescribing 
hormonal IUDs, and these two groups prescribed the most LNG-IUDs two years before study 
and in study. Continuous use of hormonal IUD increased with age. Users age and ever use of 
hormonal IUD had a significant effect on the duration of LNG-IUD use. Providers experience 
related to LNG-IUD prescriptions did not affect the duration of use. 
The cumulative probability of change to another hormonal method was highest among young 
women. Continuous use of LNG-IUD increased with age, and older women were less likely 
to switch to another hormonal contraceptive method compared to younger women. These 
findings are in line with previous studies where young women have the highest premature 
discontinuation rates(3, 4). 
Discontinuation during the first months after insertion were also highest among young 
women. These discontinuations are most likely caused by difficulties related to insertion. 
Young, nulliparous women have a narrower cervical canal compared to parous women, which 
possibly can make the insertion of LNG-IUDs more difficult in these women. Lower dose 
LNG-IUDs with a smaller insertion tube diameter compared to the Mirena, have been 





The LNG-IUD is also used as treatment for heavy menstrual bleeding and in menopausal 
hormone replacement therapy to avoid endometrial hyperplasia due to estrogen 
stimulation(15, 18-20). The menopausal transition leads to irregular bleeding cycles and in 
some women may cause menorrhagia. The high rates of LNG-IUD use and continuous use 
among older women at perimenopausal age can therefore partly be due to climacteric reasons 
and not only for contraceptive purpose.  
In this study we are using the switch to another hormonal contraceptive method as a 
measurement for discontinuation. Therefore, women who discontinue their use of LNG-IUD 
without switching to another hormonal contraceptive method, for example because of 
planning pregnancy, are not reported. This action may underestimate the total number of 
terminations.  
On the other hand, women who experience bleeding disturbances with the LNG-IUD might 
also use oral contraceptive pills simultaneously to cope with this side effect. These women are 
reported with discontinuation of LNG-IUD use because of their use of an oral contraceptive 
pill. Thus, there might be women continuing in the study, who still use the LNG-IUD, but are 
denoted as quitters due to their start of using oral contraceptive pills. 
To estimate the contraceptive experience of the provider, we have used the number of LNG-
IUD prescriptions prescribed two years before study start and also assumed that the prescriber 
inserted the device. Although this might be true in many cases, it is possible that the 
prescriber and inserter of the device are different persons. Therefore, the number of IUD 
prescription may provide an estimation of providers experience related to insertion, but it is 
not an accurate measurement in this case.  
6 Conclusion  
Duration of LNG-IUD use did not vary by the contraceptive experience of the provider. Age, 
new use and continuous use of LNG-IUD was significantly related to duration of use of the 
device. The probability to switch to another hormonal contraceptive method was highest 
among young women and decreases with age. Older women were more likely to continue 
their use of the LNG-IUD. New use and continuous use of LNG-IUD were associated with 
increased probability of changing to another hormonal contraceptive method. Past use of 


































































































8 Tables  
Table 1 Characteristics of providers (%) 
 Profession provider 




Gynecologist In total 
 N=3159 N=2464 N=214 N=420 N=6257 
Age      
24-34 57,8 1,0 1,4 1,0 29,7 
35-44 27,1 22,4 24,8 23,6 24,9 
45-54 7,8 32,3 38,8 33,8 20,2 
55-64 5,5 37,7 23,4 26,7 20,2 
65-88 1,9 6,5 11,7 15,0 4,9 
Sex      
Male 40,6 66,6 67,8 49,5 52,4 
Female 59,4 33,4 32,2 50,5 47,6 
N prescriptions of 
hormonal contra-
ception last 2 yrs. 
before study start 
     
< 1 per month 42,8 1,7 55,1 23,1 25,7 
≥ 1 per month 16,6 3,5 13,1 24,8 11,9 
≥ 1 per week  40,6 94,8 31,8 52,1 62,4 
N prescription of 
LNG-IUD last 2 yrs. 
before study start 
     
< 1 per 6 months 70,0 24,3 77,6 41,7 50,3 
≥ 1 per 6 months 25,7 58,1 21,0 34,5 38,9 
≥ 1 per month 4,3 17,6 1,4 23,8 10,8 
N prescription of 
LNG-IUD in study  
     
< 1 per 6 months 56,8 26,5 69,2 43,6 44,4 
≥ 1 per 6 months 38,5 58,0 28,0 32,4 45,4 







Table 2      Characteristics of users by age (%) 
 Users age (years) 
 15-19 20-24 25-29 30-34 35-39 40-44 45-49 In total 
 N=351 N=2449 N=5381 N=9037 N=12170 N=12219 N=6892 N=48499 
Health region         
East Norway 47,3 44,4 46,7 50,7 51,5 49,8 51,7 50,1 
Vest Norway 24,2 25,8 26,9 25,4 24,2 24,5 22,9 24,7 
Central Norway 13,7 15,9 15,8 14,5 14,4 15,5 15,2 15,1 
North Norway 14,8 13,9 10,6 9,3 9,8 10,1 10,1 10,2 
Ever use of 
hormonal IUD 
        
New use 99,4 94,2 86,4 76,2 60,6 50,2 49,9 64,2 
Continuous use 0,6 3,9 9,1 16,4 27,3 33,8 30,9 24,0 
Past use 0 2,0 4,5 7,5 12,1 16,0 19,2 11,8 
Continuous use 
from 
        
No previous use 12,0 8,0 12,1 15,3 23,3 32,2 39,9 24,3 
Pause 60,4 69,4 64,1 55,7 38,6 28,3 25,9 41,9 
COC 13,1 7,1 4,5 4,1 4,3 2,5 1,5 3,6 
POP 8,5 7,3 8,0 6,5 4,6 1,8 0,9 4,3 
Patch 2,0 0,7 0,3 0,2 0,2 0,1 0,1 0,2 
Vaginal ring 0,9 1,1 0,6 0,5 0,4 0,2 0,2 0,4 
DepoProvera 1,7 1,1 0,7 0,6 0,8 0,7 0,5 0,7 
Implants 0,9 1,4 0,5 0,7 0,6 0,3 0,2 0,5 
Hormonal IUD 0,6 3,9 9,1 16,4 27,3 33,8 30,9 24,0 
Profession 
provider 
        
No specialty 47,6 47,5 42,4 35,7 31,7 28,1 26,2 32,9 
General pract. 35,0 41,6 44,0 49,0 50,8 50,1 46,2 48,3 
Other medical sp 0,9 1,8 1,8 1,5 1,6 1,6 1,5 1,6 
Gynecologists 16,5 9,1 11,7 13,8 15,8 20,2 26,1 17,2 
Provider sex         
Male 47,6 44,0 44,2 43,7 46,1 47,6 48,3 46,0 
Female 52,4 56,0 55,8 56,3 53,9 52,4 51,7 54,0 
Provider age (yrs.)         
24-34 29,6 27,8 23,3 17,6 14,3 12,8 11,5 15,9 
35-44 23,9 29,5 29,0 28,4 24,6 20,8 19,3 24,3 
45-54 24,2 20,7 24,5 27,7 30,3 31,7 29,6 28,9 
55-64 17,4 18,7 18,9 21,8 25,5 28,3 31,2 25,2 




        
No previous 
prescriptions 
12,0 8,0 12,1 15,3 23,3 32,2 39,9 24,3 
Not same MD 68,1 62,6 54,7 48,8 41,8 34,6 30,0 42,3 

















No specialty 1,01 0,99 1,04 
General practitioner 1,00   
Other medical specialist 1,02 0,95 1,10 
Gynecologists 0,99 0,97 1,02 
    
Age user (years)    
< 20 1,97 1,77 2,19 
20-24 1,70 1,63 1,78 
25-29 1,37 1,32 1,41 
30-34 1,17 1,14 1,21 
35-39 1,0   
40-44 0,96 0,94 0,99 
45-49 0,96 0,93 0,99 
Ever use of hormonal IUD    
New use 1,10 1,08 1,13 
Continuous use 1,05 1,01 1,08 
Past use 1,0   
Hormonal IUD experience inserter 
(average no. prescriptions hormonal 
IUDs 2008-09) 
   
< 1 per 6 months 1,01 0,99 1,04 
≥ 1 per 6 months 1,00 0,98 1,03 































Referanse: Sivin I, el Mahgoub S, McCarthy T, et al: Long.-term contraception with the 
levenogestrel 20 mcg/day (LNg 20) and copper T 380Ag intrauterine device: a five-year 
randomized study. Contraception 1990;42:361-378. 
Design: RCT 
Grade:    
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Sammenligne bruken av 
LNG-IUD og kobber 
spiral (TCu 380Ag) over 
5 år i en randomisert 
studie.  
Inkludert: Fertile kvinner 




kobber eller hormonspiral, 
PID etter siste graviditet og 
ektopisk graviditet.  
 
Oppfølging: 1, 3, 6 og 12 
mnd etter innsettelse. Hvert 
halvår deretter med 
gynekologisk us.  
 
Randomisering utført ved 
bruk av lineær kongruent 
algoritme. Spiral ble pakket i 
nummerert konvolutt i 
henhold til randomisering, og 
ble åpnet rett før innsettelse.  
 
Datagrunnlag:  
LNG-IUD: n= 1124 
TCu 380Ag: n = 1121  
Eksponeringsvariabler: 
Ingen signifikant forskjell 
mellom gruppene mtp alder, 
paritet, antall mnd siden siste 
graviditet, ønske om flere 
barn, tidligere brukt IUD, PID 





Ingen.   
Statistiske metoder: 
Aktuarisk livstabell (Tietze), 
modifisert av Jain og Sivin. 
5-års kontinuasjonsrate:  
LNG-IUD: 33,0 per 100 
TCu 380Ag: 40,6 per 100 
(P<0,001) 
Amenore hos LNG-brukere 
hovedårsak til ulik 
kontinuasjonsrate.  
 
Gross kumulativ graviditet 
over 5 år: 
LNG-IUD: 1,1 +-0,5 pr 100 
TCu 380Ag: 1,4 +-0,4 pr 100 
Ingen signifikant forskjell 
mellom de to gruppene.  
 
Expulsion: 
Høyest 1. år etter innsettelse 
for begge typer spiral. 
Expulsion fra 2.-5.år, 
kumulativ rate: 
LNG-IUD: 5,9 +-1,0 per 100 
TCu 380Ag: 1,9 +-0,5 per 100 
(P<0,05) 
 
Kumulativ 5-års rate, fjerning 
pga:  
Amenore:  
LNG-IUD: 19,7 +-1,6 per 100 




LNG-IUD: 15,4 +- 1,4 per 100 
TCu 380Ag: 23,3 +-1,6 per 100 
(P<0,01) 
 
Los to follow-up over 5 år: 
LNG-IUD: 127 (11,3%) 






• Er formålet med studien 
klart formulert? Ja 
• Ble utvalget fordelt til de 
ulike gruppene med 
randomiseringsprosedyre? 
Ja 
• Ble alle deltakerne gjort 






Deltakere ble blindet 
• Var guppene like ved 
starten? Ja 
• Ble gruppene behandlet 
likt? Ja 
• Hva er resultatene? Få 
graviditeter ved bruk av 
begge typer spiral. Flere 
som avslutter bruk av 
LNG-IUD hovedsakelig 
pga amenore. 
• Kan resultatene overføres 
til praksis. Ja 
• Ble alle utfallsmål vurdert? 
Ja 
• Er fordelene verdt 
ulemper/kostnader? Ja 
• Annen litteratur som styrker 
resultatene? Ja 




  Styrker:  
- RCT-studie 
- Mange deltakere 
- Like grupper ved studiestart 
   





Få graviditeter ved bruk 



















År data innsamling 
1981–1986, oppfølging 







Referanse: Kerstin Andersson, Viveca Odlind, Göran Rybo; Levenorgestrel-releasing and 
copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. 
Contraception 1994;49:56-72  
 
Design: RCT 
Grade:    
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Sammenligne 
LNG-IUD og 
Nova T over 5 
års bruk i en 
RCT-studie.   
Inkludert: Friske kvinner, alder 
18-38 år, minst 1 tidligere 
graviditet, villig til indusert abort 
ved ikke-planlagt graviditet med 
LNG-IUD, pga mangelfull 
kunnskap om teratogen effekt.  
Ekskludert: Tidligere ektopisk 
graviditet, ammer, bruk av 
injiserbare steroidhormoner 




LNG-IUD: n = 1821 
Nova T: n = 937 
Gruppene var like mtp alder og 
paritet.  
 
IUD innsatt 3-10 dager etter 
menstruasjonsstart, evt i 
forbindelse med abort i 1. 
trimester.  
Oppfølging etter 3 og 12 mnd, 
deretter årlig opptil 5 år.  
 
Kvinner oppfordret til å notere 
blødningsmønster de første 12 
mnd i spesielt designet tabeller.  
 
Eksponering: Innsettelse av 
LNG-IUD eller Nova T IUD.  
 
Utfall evaluert: Kontinuitet, 
graviditet og utstøtning. 
Diskontinuitet grunnet 
blødningsforstyrrelser, 
amenore, smerter, PID, andre 
medisinske og personlige 
årsaker, hormonelle og 
subjektive bivirkninger. 
Planlegging av graviditet- Effekt 
på Hb og vekt.  
 
Statistiske metoder: BMDP, 
livstabell for graviditet og 
diskontinuering (Tietze & 
Lewit). 
Antall som fullførte 5 år: 
Nova T: 315 kvinner (44,5%) 
LNG-IUD: 736 kvinner (46,9%) 
 
“Lost to follow up”:  
Nova T: 133 kvinner (14%) 
LNG-IUD: 115 kvinner (6,3%) 
 
5-års kumulativ graviditetsrate:  
Nova-T: 5,9 
LNG-IUD: 0,5  
P <0,001 
 
Kumulativ rate fjerning pga 
blødningsforstyrrelser: 
Nova T: 20,7 
LNG-IUD: 13,7 
(P < 0,01) 
Signifikant flere fjernet Nova T 
grunnet kraftig 
menstruasjonsblødning og forlenget 
blødning.  
 
Kumulativ rate fjerning pga 
amenorrhea: 
Nova T: 0,0 
LNG-IUD: 6,0 
(P < 0,001) 
 
Kumulativ rate fjerning pga PID: 
Nova T: 2,2 
LNG-IUD: 0,8 
(P < 0,05) 
Signifikant økt forekomst av PID 
blant kvinner ≤ 25 år med Nova T 
sammenlignet med LNG-IUD. 
 
Hormonelle bivirkninger:  
Nova T: 2,0 
LNG-IUD: 12,1 







• Er formålet med 
studien klart formulert? 
Ja.	
• Ble utvalget fordelt til 




yre  ikke beskrevet. 	
• Ble alle deltakerne 




ell blindet mht 
gruppetilhørighet? Nei.	
• Var guppene like ved 
starten? Forskjell i 
størrelsen på 
gruppene. 	
• Ble gruppene 
behandlet likt? Ja	
• Kan resultatene 
overføres til praksis? 
Ja.	
• Ble alle utfallsmål 
vurdert? Ja.	
• Har resultatene 
plausible forklaringer? 
Ja.	
• Annen litteratur som 
styrker resultatene? Ja. 
 Styrke: 
• RCT-studie. 
• Mange deltakere. 
• Tar hensyn til flere 
relevante utfallsmål. 
 Svakhet:  
• Randomiseringsprosedy
re ikke forklart.  
• Ulik størrelse på de to 
gruppene. 
• Pasienter ikke blind 
Konklusjon 
Ved bruk av 







blødning og økt 
Hb. LNG-IUD 



















Referanse: Tiina Backman, Sakke Huhtala, Riitta Luoto, Juhani Tuominen, Ilkka 
Rauramo and Markku Koskenvuo; Advance Information Improves User Satisfaction With 
the Levonorgestrel Intrauterine System. Obstetrics & Gynecology 2002;99:608-613 
Design: Pasientserier 
Grade:    
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Se på påvirkning av 
avansert informasjon 
som gis om LNG-
IUD og effekt på 
pasienttilfredshet.  
Populasjon:  
Alle kvinner som fikk 
innsatt LNG-IUD i Finland 
mellom 1990-1993 ble 
spurt om å delta i studien. 
26 630 kvinner ble med. 
I 1996 ble spørreskjema 
med 75 spm sendt til 
23,885 kvinner. Etter 3 
påminnelser ble 75% av 
skjemaene fylt ut.  
Usignerte skjema og der 
fødselsdato ikke stemte 
med personnummer ble 
ekskludert (n=554).  
Antall skjema som ble 
analysert var 17 360.  
Gjennomsnittsalder var 40 
år (standardavvik 6,4). 
99,3% hadde født barn, 
78,1% hadde født to eller 
tre. 83% av kvinnene var 
gift eller i samboerskap. 
23% hadde gjennomgått 
spontan eller indusert 
abort. 4,8% hadde tidligere 
ektopisk gravditet.  
Utfall – hoved utfall: 
Hvor fornøyd brukerne var 
med LNG-IUD og hvor mye 
info de hadde fått om 
prevensjonsmetoden før 
innsettelse.   
Statistiske metoder: 
SAS software 8,0 
Kumulativ logistisk 
regresjonsnalayse basert 
på femtrinns-skala for 
tilfredshet som avhengig 
variabel. 
OR beregnet med gruppen 
som mottok svært lite info 
som referanse, justert for 
relevante symptomer og 
alder. 
  
74% kvinner svært eller ganske 
fornøyd med LNG-IUD.  
8,3% kvinner ved svært eller ganske 
misfornøyd.  
 
Brukertilfredshet økte med alder.  
Brukertilfredshet varierte ikke 
betydelig med utdanning, sivilstatus, 
paritet, tidligere prevensjon, røyking 
og alkohol,  
  
Mye info om: 
- Blødningsforstyrrelser og 
svært fornøyd: OR = 3,28 
(95% KI, 2,61 – 4,10).  
 
- Total/tidvis bortfall av 
menstruasjon og svært 
fornøyd: OR = 4,96 (95% KI, 
4,15-5,93) 
 
- PID og fornøyd: OR = 2,52 
(95% KI, 2,24 – 2,82). 
 
- Risiko for graviditet og 
fornøyd: OR = 2,27 (95% KI, 
1,99 – 2,59)  
 
- Fet hud/hår og svært 
fornøyd: OR = 2,35 (95% KI, 
2,09 – 2,65) 
 
- Humørsvingninger og svært 
fornøyd: OR = 2,32 (95% KI 









 Sjekkliste:  
• Er formålet klart formulert? 
Ja. 
• Var studien basert på et 
tilfeldig utvalg fra en egnet 
pasientgruppe? Ja. 
• Var inklusjonskriteriene klart 
definert? Ja. 
• Var alle pasientene i samme 
stadium av sykdommen? Nei 
• Var responsraten høy nok? 
Ja. 
• Frafallsanal? Nei 
• Ble det brukt objektive 
kriterier for å 
vurdere/validere 
endepunktene? Nei. 
• Ved sammenligninger av 
pasientserier, er seriene 





hensyn til i design/anal? Ja, 
men ikke justert for 
brukervarighet.  
• Var registreringen 
prospektiv? Nei. 
• Kan resultatene overføres til 
praksis? Ja.  
• Annen litteratur som støtter 
resultatene? Ja. 
  
Styrke: Stor studiepopulasjon  
Svakhet: Spørreundersøkelse er 
basert på pasientenes hukommelse 







Info som gis ved 
innsettelsestidspunkt 
er sterkt assosiert 
med økt 
brukertilfredshet 



















Referanse:  Michael Cox, John Tripp, Sarah Blacksell: Clinical Performance of the 
levenorgestrel intrauterine system in routine use by the UK Family Planning and 
Reproductive Health Research Network: 5-year report. J Fam Plan Reprod Health Care 
2002;28:73-7 
Design: Pasientserier 
Grade:    
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Fastslå effekten av 
LNG-IUS blant 
britiske kvinner ved 
bruk over 5 år.  
 
Inkludert: Kvinner 18 – 
45 år, som tidligere har 
født, frisk, normal 
menstruasjonssyklus. 
LNG-IUS innsatt mer enn 
6 uker etter fødsel.  
N= 678 
 
Ekskludert: Kvinner > 45 
år, nulliparous, innsettelse 
nr 2 eller mer, 
akuttprevansjon, gravid 
ved innsettelse, mindre 
enn 6 uker etter fødsel, 
samtidig bruk av POP, 
COC, HRT, pessar, 
spermisid.  
 
Oppfølging: 3 mnd, 12 
mnd og årlig deretter 
opptil 5 år.  
Utfall: Vurdere effekten 




smerter, PID, planlegging 
av graviditet, andre 





hendelser klassifisert etter 





Gross kumulativ rate 5-års bruk: 
Graviditet: 1,0 (95% KI, 0,3 – 2,4) 
Utstøtning: 5,9 (95% KI, 3,9 – 7,9) 
 
Gross kumulativ 5-års rate, 
fjerning grunnet: 
- Blødningsforstyrrelser og 
smertefull blødning: 16,7 (KI 




- Smerter: 4,3 (95% KI, 2,4 – 
6,2) 
- PID: 1,2 (95% KI, 0,4 – 2,5) 
- Andre plager assosiert med 
IUS: 20,8  
(95% KI, 17,0 – 24,7). Flest 
grunnet oligo/amenore. 
 
- Andre årsaker: 15,0 (KI 
95%, 11,3 – 18,7)  
- Planlegging graviditet: 14.3 
(95% KI 10,7-17,9)  
- Medisinsk ikke-relatert 






• Er formålet klart formulert? Ja 
• Var studien basert på et 
tilfeldig utvalg fra en egnet 
pasientgruppe? Usikkert.  
• Var inklusjonskriteriene klart 
definert? Ja 
• Var alle pasientene i samme 
stadium av sykdommen? Ja, 
minst 6 uker postpartum. 
• Var responseraten høy nok? 
Ja. 
• Frafallsanal.? Nei 
• Ble det brukt objektive 
kriterier for å vurdere/validere 
endepunktene? Ja.   
• Ved sammenligninger av 
pasientserier, er seriene 




faktorer beskrevet/tatt hensyn 
til i design/anal? Ja 
• Var registreringen prospektiv? 
Ja. 
• Var oppfølgningen lang nok? 
Ja. 
• Var oppfølgningen tilstrekkelig 
for å nå endepunktene? Ja. 
• Kan resultatene overføres til 
praksis? Nei. 
• Annen litteratur som støtter 
resultatene? Ja. 
 
• Styrke: Følger pasientene 
over 5 år. 
• Svakhet: Kun 1 pasientserie, 
ingen gruppe til 
sammenligning. Pasienter 
rekruttert fra klinikker involvert 




Det er behov for 
rådgivning til 
kvinner ang tidlig 
blødningsproblemer 
inkl mulighet for 
oligomenore og 
amenore. Dette 
anses som viktig for 
kontinuasjon slik at 




År data innsamling 












Referanse: Gemzell-Danielsson K, Schellschmidt I, Apter D: A randomized, 
phase II study describing the efficiacy, bleeding profile, and safety of two low-
dose levenorgestrel-releasing intrauterine contraceptive systems and Mirena. 
Fertility and Sterility 2012:97;616-622 
Design: RCT 
Grade:    ( ) 
Formål Materiale og metode Resultater Diskusjon/kommentarer 
Å identifisere en 
passende dose 
for en ny LNG-
IUS.  
Rekruttering deltakere: 
Kvinner som ønsker prevensjon 
på klinikkene og via reklame.  
Inkludert: 
Friske parous og nulliparous 
kvinner, alder 21-40 
år.Ultralydresultat med 
uteruskavitet som egner seg for 
str på Mirena. Regelmessig 
menstruasjonssyklus (21-35 d). 
Seksuelt aktive. 
Ekskludert: Laktasjon, vaginal 
fødsel, keisersnitt eller abort ≤ 
12 uker før screening. 
Deformert uteruskavitet (f.eks. 




IUD (eks, brystkreft, kongenital 
uterus anomali.  
Datagrunnlaget: 742 kvinner 
randomisert i 3 grupper, fulgt i 3 
år. LNG-IUS 12, n=239; LNG-
IUS16, n: 245; Mirena, n=254.  
Utfall: Graviditet, bivirkninger 
relatert til progestin, 
blødningsmønster, plassering 
av IUD, endometrietykkelse, 
ovariestørrelse, vansker og 
smerter ved innsettelse, 






SAS, Pearl index med 










for alle tre typer IUD. 
 
Ovariecyster: 
LNG-IUS 12: 5,9% 
LNG-IUS 16: 8,6% 
Mirena:22,0%  
P < 0,0001 
 
Avsluttet bruk av IUD 
grunnet bivirkninger: 
LNG-IUS 12: 15% 
LNG-IUS 16: 15% 
Mirena: 17% 
Vanligste: Akne, 
vaginalblødning, endring i 
humør, magesmerter og 
ovariecyste.  
Utstøting av LNG-IUD:  
LNG-IUS 12: 0,4% 
LNG-IUS 16: 2% 
Mirena: 1,6% 
Fravær av dysmenore 
ved start og studieslutt: 
LNG-IUS 12: 49,9% og 
82,0% 
LNG-IUS 16: 49,0% og 
81,0% 
Mirena: 43,7% og 83,7% 
P = 0,73 
 
Innsetting av IUD 
rapportert som "enkel" 
av lege: 
LNG-IUS 12 & 16: 94,0% 
Mirena: 86,2%  
P < 0,001 
Pas rapporterte om mindre 
smerter ved innsetting av 
LNG-IUS 12 & 16 
sammenlignet med Mirena 
(P<0,001) 
 Sjekkliste: 
• Er formålet klart formulert? Ja 
• Var gruppene like ved starten? 
Ikke like mtp røyking.  
• Randomiseringsprosedyre? Bruk 
av dataprogram og forseglede 
konvolutter.  
• Ble deltakere/studiepersonell 
blindet mht gruppetilhørighet? 
Kun deltagere, ikke mulig å blinde 
personell.  
• Ble gruppene behandlet likt 
utover «intervensjonen»?Ja  
• Primære endepunktet – validert? 
Ja 
• Ble deltakernne gjort rede for på 
slutten av studien? Lost to follow-
up ikke besrkevet. 
• Kan resultatene overføres til 
praksis? Ja 
• Ble alle utfallsmål vurdert? Ja 
• Er fordelene verdt 
ulemper/kostnader? Ja 
• Annen litteratur som styrker 
resultatene? Ja 
 Hva diskuterer forfatterne som: 
-styrke: RCT, mange deltagere 
-svakhet: Lost,to follow-up ikke beskrevet.  



















og var godt 
tolerert 
sammenlignet 
med Mirena.   
Land 
Finland, Sverige, 











Referanse: Varila E, Wahlström T, Rauramo I; A 5-year follow-up study on the use 
of a levenorgestrel intrauterine system in women receiving hormone replacement 
therapy. Fertility and sterility 2001;76:696-673 
Design: Kohortestudie 
Grade:    





effekten av å 
bytte LNG-IUD 
etter 5 års 
kombinert bruk 
med estrogen.  
Inkludert: 39 postmenopausale 
kvinner, fullført 12 mnd studie 
mtp LNG-IUD + HRT. HRT 
grunnet sympt. overgangsalder. 
Ekskludert: Tidligere 
endokarditt, malignitet,PID, 
infeksjon i genitalia, submucosal 
leiomyom, uforklarlig 
uterusblødning, alvorlig 
hirsutisme, DVT.  
29 kvinner fikk tilbud om å 
fortsette HRT +LNG-IUD..   
Behandlingsfri 3 mnd før ny 
LNG-IUD: n = 7 
Umiddelbar ny LNG-IUD: n = 22 
3 mnd uten behandling etter 
fjerning av 1. à vurdere 
endometriets tilheling 
Intervensjon: Endometrieprøver 
til histolog, vurdering av 
endometrietykkelse, UL ved 
fjerning LNG-IUD, 
blødningsdagbok ført av pas.  
 
Utfall – hoved utfall: 
Endometriets histologi og 
tykkelse, effekter av østrogen og 
progestin. Blødningsmønster via 
«blødningsdagbøker». Vurdering 
av insetting, fjerning og 
reinnsetting LNG-IUD av pas og 
lege.   
Histopat. Endometriet:  
Østrogen stim: 0 = atrofisk 
endometrium, 1 = lite stim av 
atrofisk endometrium, 2= sterkere 
østrogenstim., 3 = slutten av 
normal proliferativ fase i syklus.  
Progestineffekt vurdert med 
normsl syklus som ref. på samme 
måte.  
Statistiske metoder: Resultater 
angitt i prosent, gjennomsnitt 
med standardavvik eller median 
med omfang.  
 
Hovedfunn (etter 5 års bruk) 





endometriet vurdert som 
moderat (2) og sterk (3) i 28 
av 29 biopsier. Ingen prøver 
med endometriehyperplasi. 
Østrogenstim vas synlig i alle 
prøver, med skår mellom 1 og 
2 à suppresjon av 
endometriet.  
Innsetting (1. og 2.): 
Ingen smerter: 19 og 18 
Milde smerter: 13 og 10 
Moderate smertert: 7 og 0 
Sterke smerter: 1 og 1 
Innsetting enkel: 26 og 14 
Innsetting vanskelig: 27 og 2 
 
Blødning: 
35 av 39 kvinner rapporterte 
ingen blødningsdager. 10 
kvinner rapporterte 
småblødninger det 1. året. 25 
kvinner med amenore. 
Kvinner med behandlingsfri 3 
mnd rapporterte om 
småblødninger (ikke mer enn 
11 dager) i perioden uten 
behandling. Median 
blødningsdager = 0 tre mnd 
etter ny innsetting hos begge 
grupper.  
 Sjekkliste:  
• Er formålet klart formulert?Ja 
• Var studien basert på et 
tilfeldig utvalg fra en egnet 
pasientgruppe? Usikkert 
• Var inklusjonskriteriene klart 
definert? Ja 
• Var alle pasientene i samme 
stadium av sykdommen? Ja 
• Var responseraten høy nok? Ja 
• Ble det brukt objektive kriterier 
for å vurdere/validere 
endepunktene? Ja 
• Ved sammenligninger av 
pasientserier, er seriene 
tilstrekkelig beskrevet? Nei 
• Er 
prognostiske/konfunderende 
faktorer beskrevet/tatt hensyn 
til i design/anal?Ja 
• Var registreringen 
prospektiv?Ja 
• Var oppfølgningen lang nok!Ja 
• Var oppfølgningen tilstrekkelig 
for å nå endepunktene? Ja 
• Kan resultatene overføres til 
praksis? Liten pasientgruppe. 
• Annen litteratur som støtter 
resultatene?Ja 
  
      Hva diskuterer forfatterne som: 
• Styrke: Lang nok 
oppfølging, alle 
endepunktene vurdert. 
• Svakheter: Lite 
pasientgrunnlag, ulik 
størrelse på gruppene.  















de fleste kvinner 
induserer den 
amenore, som 
kun kortvarig 
påvirkes av 
bytting av LNG-
IUD.  
Land 
Finland 
År data 
innsamling 
Ikke beskrevet 
	
